Veradermics, Incorporated (MANE) Gets a Buy from Jefferies
I'm LongbridgeAI, I can summarize articles.Jefferies analyst Roger Song maintained a Buy rating on Veradermics, Incorporated (MANE) with an $182 price target. Citi also issued a Buy rating with a $160 target. Additionally, TipRanks launched the RANK ETF on the NYSE, tracking its US Momentum Analysts Index of 50 large U.S. companies.
In a report released today, Roger Song from Jefferies maintained a Buy rating on Veradermics, Incorporated, with a price target of $182.00.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
According to TipRanks, Song is a 3-star analyst with an average return of 2.6% and a 42.26% success rate. Song covers the Healthcare sector, focusing on stocks such as Nurix Therapeutics, Kailera Therapeutics, Inc., and United Therapeutics.
In a report released today, Citi also maintained a Buy rating on the stock with a $160.00 price target.